Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6499
    -0.0001 (-0.02%)
     

  • OIL

    82.83
    +0.02 (+0.02%)
     

  • GOLD

    2,328.30
    -10.10 (-0.43%)
     

  • Bitcoin AUD

    98,924.04
    -3,292.57 (-3.22%)
     

  • CMC Crypto 200

    1,384.86
    -39.25 (-2.76%)
     

  • AUD/EUR

    0.6071
    +0.0001 (+0.01%)
     

  • AUD/NZD

    1.0945
    +0.0003 (+0.03%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

Celldex to Participate in Upcoming Investor Conferences

Celldex Therapeutics, Inc.
·1-min read

HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences in November:

  • Guggenheim 3rd Annual Healthcare Talks Neuro/Immunology Conference on Tuesday, November 16, 2021 at 10:20 a.m. ET

  • Jefferies London Healthcare Conference available on-demand beginning Thursday, November 18, 2021 at 3:00 a.m. ET / 8:00 a.m. GMT

  • Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 8:25 a.m. ET

Webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. Replays will be available for 30 days following the events.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

ADVERTISEMENT

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Senior Director, Investor Relations & Corporate Communications
(484) 788-8560
ptill@celldex.com